Old.nbpharma.com is a subdomain of Nbpharma.com, which was created on 2008-02-08,making it 16 years ago.
Description:NewBridge Pharmaceuticals offers innovative pharmaceutical solutions in oncology, immunology, neuroscience, metabolic & GI disease, and medical nutrition....
Keywords:NewBridge Pharmaceuticals, oncology, immunology, neuroscience, metabolic, GI disease, medical nutrition, pharmaceutical solutions, global business network...
Discover old.nbpharma.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
HomePage size: 76.799 KB |
Page Load Time: 0.82143 Seconds |
Website IP Address: 104.21.73.198 |
Aridis Pharmaceuticals - Welcome investors.aridispharma.com |
Clinical Trials | Regeneron Pharmaceuticals clinicaltrials.regeneron.com |
Investor Relations :: CNS Pharmaceuticals, Inc. (CNSP) ir.cnspharma.com |
Mirum Pharmaceuticals, Inc. - Investor Relations ir.mirumpharma.com |
The Power of the Microbiome | Ferring Pharmaceuticals microbiome.ferring.com |
Investor Relations - Supernus Pharmaceuticals ir.supernus.com |
Amneal Pharmaceuticals, Inc. - Investor Relations investors.amneal.com |
Investors :: Conatus Pharmaceuticals Inc. (CNAT) ir.conatuspharma.com |
Eagle Pharmaceuticals Investor Center | investor.eagleus.com |
Alcon Completes Acquisition of Aerie Pharmaceuticals | Alcon.com investors.aeriepharma.com |
Investor Relations - Spectrum Pharmaceuticals, Inc. investor.sppirx.com |
TopRx – Home – National Supplier of Generic Pharmaceuticals netstore.toprx.com |
Ligand Pharmaceuticals Incorporated - Investor Relations investor.ligand.com |
NIT Newbridge IT Department it.newbridgesecurities.com |
Lifeline Pharmaceuticals, LLC’s Login Page | Lifeline Pharmaceuticals, LLC lifelinepharm.tracktracerx.com |
NewBridge Pharmaceuticals https://old.nbpharma.com/ |
About NewBridge https://old.nbpharma.com/about/ |
Executive Team https://old.nbpharma.com/executive-team/ |
Careers https://old.nbpharma.com/careers/ |
abiogen https://old.nbpharma.com/abiogen/ |
Logos https://old.nbpharma.com/logos/ |
perrigo https://old.nbpharma.com/perrigo/ |
Immunology https://old.nbpharma.com/immunology/ |
Our Partners https://old.nbpharma.com/our-partners/ |
Products | NewBridge Pharmaceuticals https://old.nbpharma.com/products/ |
oncotype_dx | NewBridge Pharmaceuticals https://old.nbpharma.com/products/oncology/oncotype_dx/ |
Latest News | NewBridge Pharmaceuticals https://old.nbpharma.com/latest-news/ |
Oncology, breast cancer,thyroid cancer | NewBridge Pharmaceuticals https://old.nbpharma.com/oncology/ |
halaven | NewBridge Pharmaceuticals https://old.nbpharma.com/products/oncology/halaven/ |
Board of Directors | NewBridge Pharmaceuticals https://old.nbpharma.com/board-of-directors/ |
Date: Wed, 15 May 2024 10:57:25 GMT |
Content-Type: text/html; charset=UTF-8 |
Transfer-Encoding: chunked |
Connection: keep-alive |
Vary: Accept-Encoding, X-Forwarded-Proto,Accept-Encoding |
Last-Modified: Wed, 15 May 2024 10:08:56 GMT |
Referrer-Policy: no-referrer-when-downgrade |
CF-Cache-Status: DYNAMIC |
Report-To: "endpoints":["url":"https:\\/\\/a.nel.cloudflare.com\\/report\\/v4?s=%2BKdGVw77iL4OwgLVL4KIq%2BqzWYCAPm4U35Ky7zNJOvpOwEW21gMCmayyeHyDhfddt22mOe7f9mx2lg5XM%2BpOqKN6WkeMhTp40acSqTfSk3J6494qp4Gad1J4oFXvoC%2FvTS9vPOcyiSW2o7vRCcq6"],"group":"cf-nel","max_age":604800 |
NEL: "success_fraction":0,"report_to":"cf-nel","max_age":604800 |
Server: cloudflare |
CF-RAY: 88429b67092e7c97-LAX |
alt-svc: h3=":443"; |
content="width=device-width, initial-scale=1.0" name="viewport"/ |
content="IE=edge" http-equiv="X-UA-Compatible" |
content="text/html; charset=utf-8" http-equiv="Content-Type"/ |
content="max-image-preview:large" name="robots"/ |
content="en_US" property="og:locale"/ |
content="NewBridge Pharmaceuticals |" property="og:site_name"/ |
content="website" property="og:type"/ |
content="NewBridge Pharmaceuticals" property="og:title"/ |
content="https://old.nbpharma.com/" property="og:url"/ |
content="summary" name="twitter:card"/ |
content="old.nbpharma.com" name="twitter:domain"/ |
content="NewBridge Pharmaceuticals" name="twitter:title"/ |
content="WordPress 5.5.14" |
Pharmaceuticals hello Home company Back About Mission, Vision & Values Executive Team Board of Directors Investors partnerships Back Region & Strategy Why Partner with Us Our partners products Back Oncology Immunology Neuroscience Metabolic & GI Disease Medical Nutrition Media Back Press Releases News careers Contact Us Back Contact Us PATIENT CONSENT FORM Search for: Bridge the Gap ’s global business network and unique value proposition provide a platform to bridge the access gap of global innovation and successful reach within the MENA region Accessing Innovation - a specialty company providing a one stop solution to pharmaceutics, biological, genomics and other innovative healthcare companies seeking to access the MENA markets. Serving Patients is committed to providing advanced treatment options through innovative healthcare products to bridge the unmet medical needs of patients in the MENA region 1 2 3 LATEST NEWS November 18, 2021 BioCryst Announces Approval of ORLADEYO® (berotralstat) in United Arab Emirates Company selects Pharmaceuticals as regional distributor in Gulf Cooperation Council RESEARCH TRIANGLE PARK, N.C.,... November 14, 2021 BeiGene and Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma BeiGene and Pharmaceuticals are working together to rapidly advance BRUKINSA in the Middle East and North African (MENA) region... July 20, 2021 Pharming signs agreement with Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa Pharming Group N.V. (Pharming” or the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces it has entered... Accessing Innovation, Serving Patients ’s global business network, unique value proposition, and its one-stop solution to pharmaceutical, biologics, genomics and other innovative healthcare companies provide a platform both for accessing global innovation – and ensuring successful reach within the MENA Region. is committed to bridge the unmet medical needs of, and provide advanced treatment to patients in the Region. ABOUT NEWBRIDGE provides essential access to build value for pharmaceutics and biotech companies. learn more WHY PARTNER WITH US provides access to innovative therapeutics and diagnostics for patients in the MENA Region learn more OUR PRODUCTS has a commercial presence covering 20 plus countries in its network in the MENA Region learn more 1 null null WHO WE ARE AND WHAT WE DO is a regional specialty company providing a one-stop-solution to pharmaceutics, biological, genomics and other innovative healthcare companies. Our focus is on in-licensing and commercializing FDA and EMA/European approved innovative therapeutics and diagnostics that address unmet medical needs of diseases with high prevalence within the MEN A regio n . Our business model is designed to provide the partners we represent with a full range of services and multiple functions to bring long term commercial excellence and build value to our licensed brands across multiple geographies. Our success is driven by highly talented teams who come to with a proven track record and experience in the pharmaceutical industry regionally and globally. NEWBRIDGE PHARMACEUTICALS PARTNERS BECOME A PARTNER New Bridge PharmaceuticalsNew Bridge Pharmaceuticals MENA Regional Headquarters P.O. Box 500618,Dubai Science Park Towers 17th Floor, North Tower, Al Barsha South 2 Dubai United Arab Emirates Tel: +971 4 429 8700 Fax: +971 4 429 8677 Website: https://old.nbpharma.com Map: Google Map Pharmaceuticals Limited Trident Chambers PO Box 146 Road Town Tortola British Virgin Islands Alliance Network Algeria, Bahrain, Egypt, Iraq, Jordan, KSA, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Tunisia, UAE, Yemen Home company partnerships products media careers contact us In the event of an adverse event occurring from any of the licensed products, kindly report them to the Safety Mailbox at [email protected] , or call us on +971564034031 or +971564152222 في حالة حدوث اي اثار جانبية من اي من المنتجات المرخصة لشركة نيوبردج يرجي الابلاغ عنها عن طريق البريد الألكتروني أو الاتصال على الهاتف رقم +971564034031 أو +971564152222 [email protected] PO Box 500618, Dubai Science Park Towers, 17th Floor, North Tower, Al Barsha South 2, Dubai, United Arab Emirates © 2023 Pharmaceuticals - All rights reserved Designed & Built by Pink Entropy We use Cookies and other tracking technologies to improve your browsing experience on our website,to show you personalized content and targeted ads, to analyze our website traffic, and to understand where our visitors are coming from.By browsing our website , you consent to our use of cookies and other tracking technologies . Privacy &...
Domain Name: NBPHARMA.COM Registry Domain ID: 1398846024_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2023-01-05T15:05:21Z Creation Date: 2008-02-08T22:15:57Z Registry Expiry Date: 2026-02-08T22:15:57Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: ROSE.NS.CLOUDFLARE.COM Name Server: SETH.NS.CLOUDFLARE.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-18T02:43:53Z <<<